Long-Term Investors in shares of Biogen Inc. (NASDAQ: BIIB) should contact the Shareholders Foundation in connection with Investigation over potential Wrongdoing

An investigation was announced for long-term investors in shares of Biogen Inc. (NASDAQ: BIIB) concerning potential breaches of fiduciary duties by certain directors and officers of Biogen Inc.

Investors who are current long term investors in Biogen Inc. (NASDAQ: BIIB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: BIIB stocks follows a lawsuit filed against Biogen Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: BIIB stocks, concerns whether certain Biogen Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Colorado the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures, that accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries, that Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries, that the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm, that Biogen overstated the strength of its AD-related product portfolio, including the Company's and Eisai's efforts and success in launching and providing access to Leqembi, that Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS, that all the foregoing were likely to have a significant negative impact on Biogen's 2023 results; and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Biogen Inc. (NASDAQ: BIIB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.